Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Affect Disord ; 281: 751-758, 2021 02 15.
Article in English | MEDLINE | ID: mdl-33267979

ABSTRACT

BACKGROUND: Evidence from family and twin studies suggests that mood and anxiety disorders, and related temperamental factors may share common etiologic factors. We examine the familial aggregation and coaggregation of anxiety disorder subtypes and anxiety-related temperamental traits, and their association with mood disorders. METHODS: A total of 477 probands and 549 first-degree adult relatives from a large community based family study of affective spectrum disorders completed semi-structured diagnostic interviews and self-reported assessments of temperamental traits including: negative affectivity on the 'Positive and Negative Affect Schedule' (PANAS), neuroticism anxiety on the 'Zuckerman-Kuhlman Personality Questionnaire' (ZKPQ), and anxiety sensitivity on the 'Anxiety Sensitivity Index' (ASI). RESULTS: The anxiety-related temperamental traits of negative affectivity, neuroticism anxiety and anxiety sensitivity had significant familial specificity, even after controlling for comorbid mood and anxiety disorders in probands and relatives. Yet, these traits in probands did not predict anxiety disorders in relatives. Although some anxiety subtypes were familial, there were no longer familial links between anxiety disorder subtypes (generalized anxiety disorder, social anxiety or panic disorder) after controlling for mood disorder subtypes in probands and relatives. LIMITATIONS: Cross-sectional interviews were used to estimate disorders, and self-report measures were used for temperamental traits. CONCLUSIONS: These results confirm previous research regarding familial overlap between anxiety subtypes and mood disorders, however their shared liability cannot be fully explained by anxiety-related temperamental traits. These findings suggest that anxiety-related temperamental traits may indicate a vulnerability for mood and anxiety disorders or a potential consequence of these conditions.


Subject(s)
Anxiety Disorders , Temperament , Adult , Anxiety , Anxiety Disorders/epidemiology , Anxiety Disorders/genetics , Cross-Sectional Studies , Family , Humans , Mood Disorders/epidemiology , Mood Disorders/genetics , National Institute of Mental Health (U.S.) , United States
2.
Bipolar Disord ; 21(8): 720-740, 2019 12.
Article in English | MEDLINE | ID: mdl-31479581

ABSTRACT

OBJECTIVES: To clarify the clinical features preceding the onset of bipolar disorder (BD) has become a public health priority for the prevention of high morbidity and mortality. BD remains frequently under- or misdiagnosed, and under- or mistreated, often for years. METHODS: We assessed the predictive value of precursors and prodromes of BD. We assessed precursors of first-lifetime manic or hypomanic episodes with/without mixed features in retrospective and prospective studies. The task force evaluated and summarized separately assessments of familial risk, premorbid personality traits, retrospective, and prospective studies. RESULTS: Cyclothymic features, a family history of BD, retrospectively reported attenuated manic symptoms, prospectively identified subthreshold symptoms of hypomania, recurrence of depression, panic anxiety and psychotic features, have been identified as clinical precursors of BD. The prodromal symptoms like [hypo]mania often appears to be long enough to encourage early identification and timely intervention. CONCLUSIONS: The predictive value of any risk factor identified remains largely unknown. Prospective controlled studies are urgently needed for prevention and effective treatment.


Subject(s)
Bipolar Disorder/diagnosis , Prodromal Symptoms , Adult , Advisory Committees , Anxiety , Anxiety Disorders , Cyclothymic Disorder , Depression , Female , Humans , Male , Prospective Studies , Retrospective Studies , Risk Assessment , Risk Factors
3.
Compr Psychiatry ; 84: 7-14, 2018 07.
Article in English | MEDLINE | ID: mdl-29655654

ABSTRACT

BACKGROUND: There is substantial evidence that bipolar disorder (BD) manifests on a spectrum rather than as a categorical condition. Detection of people with subthreshold manifestations of BD is therefore important. The Hypomania Checklist-32 (HCL-32) was developed as a tool to identify such people. PURPOSE: The aims of this paper were to: (1) investigate the factor structure of HCL-32; (2) determine whether the HCL-32 can discriminate between mood disorder subtypes; and (3) assess the familial aggregation and cross-aggregation of hypomanic symptoms assessed on the HCL with BD. PROCEDURES: Ninety-six probands recruited from the community and 154 of their adult first-degree relatives completed the HCL-32. Diagnosis was based on semi-structured interviews and family history reports. Explanatory factor analysis and mixed effects linear regression models were used. FINDINGS: A four-factor ("Activity/Increased energy," "Distractibility/Irritability", "Novelty seeking/Disinhibition, "Substance use") solution fit the HCL-32, explaining 11.1% of the total variance. The Distractibility/Irritability score was elevated among those with BP-I and BP-II, compared to those with depression and no mood disorders. Higher HCL-32 scores were associated with increased risk of BD-I (OR = 1.22, 95%CI 1.14-1.30). The "Distractibility/Irritability" score was transmitted within families (ß = 0.15, p = 0.040). However, there was no familial cross-aggregation between mood disorders and the 4 HCL factors. CONCLUSIONS: Our findings suggest that the HCL-32 discriminates the mood disorder subtypes, is familial and may provide a dimensional index of propensity to BD. Future studies should explore the heritability of symptoms, rather than focusing on diagnoses.


Subject(s)
Checklist/methods , Family/psychology , Mood Disorders/diagnosis , Mood Disorders/psychology , National Institute of Mental Health (U.S.) , Adult , Aged , Aged, 80 and over , Bipolar Disorder/diagnosis , Bipolar Disorder/genetics , Bipolar Disorder/psychology , Checklist/standards , Cyclothymic Disorder/diagnosis , Cyclothymic Disorder/genetics , Cyclothymic Disorder/psychology , Depressive Disorder/diagnosis , Depressive Disorder/genetics , Depressive Disorder/psychology , Factor Analysis, Statistical , Female , Humans , Male , Middle Aged , Mood Disorders/genetics , Retrospective Studies , Substance-Related Disorders/diagnosis , Substance-Related Disorders/genetics , Substance-Related Disorders/psychology , United States/epidemiology
4.
Harv Rev Psychiatry ; 26(1): 1-7, 2018.
Article in English | MEDLINE | ID: mdl-29303917

ABSTRACT

LEARNING OBJECTIVES: After participating in this activity, learners should be better able to:• Evaluate factors that have been identified in prospective studies as predicting the onset of bipolar disorder ABSTRACT: The prodromal phase of bipolar disorder (BD) remains incompletely characterized, limiting early detection of BD and delaying interventions that might limit future morbidity and disability. Retrospective and family-risk studies have consistently found evidence of prodromal psychopathology in subjects later diagnosed with BD. Here, we review prospective studies of clinical risk factors and exposures identified before diagnosis of BD: our findings are consistent with those from retrospective and family-risk studies. Affective psychopathology often precedes diagnosis to suggest a homotypic trajectory in developing BD. Early non-affective (heterotypic) psychopathological disturbances, including anxiety and disruptive behavior disorders, as well as environmental factors and exposures, have been found in prospective studies to increase the risk of BD, but tend to lack specificity in predicting BD. Findings from prospective studies are encouragingly similar to those of retrospective and family-risk studies.


Subject(s)
Anxiety Disorders/epidemiology , Attention Deficit and Disruptive Behavior Disorders/epidemiology , Bipolar Disorder/epidemiology , Bipolar Disorder/etiology , Environmental Exposure/adverse effects , Comorbidity , Early Diagnosis , Humans , Prospective Studies , Psychopathology , Risk Factors
5.
Depress Anxiety ; 35(4): 360-371, 2018 04.
Article in English | MEDLINE | ID: mdl-29244900

ABSTRACT

BACKGROUND: Although there has been abundant research on chronic low-grade inflammation as a potential mechanism underlying the link between mood disorders and cardiovascular risk, less is known about the role of inflammatory factors and anxiety disorders. The aim of this paper is to evaluate the bi-directional associations between inflammatory markers including interleukin (IL)-6, tumor necrosis factor (TNF)-α, and high sensitivity C-reactive protein (hsCRP) with anxiety disorders and its subgroups. METHODS: The sample consisted of 3,113 participants (53.7% women; mean age: 51.0, S.D. 8.8 years), randomly selected from the general population, who underwent comprehensive somatic and psychiatric evaluations at baseline and follow-up (mean follow-up duration = 5.5 years, S.D. 0.6). Anxiety disorders were assessed with semistructured diagnostic interviews. Inflammatory biomarkers were analyzed in fasting blood samples. RESULTS: After adjustment for potential confounders, current anxiety disorders (ß = 0.09, 95% CI 0.00-0.17) and agoraphobia (ß = 0.25, 95% CI: 0.07-0.43) at baseline were associated with a steeper increase of hsCRP levels over the follow-up period. Current posttraumatic stress disorder (PTSD) was associated with a lower increase of IL-6 levels over the follow-up period (ß = -0.52, 95% CI: -1.00/-0.04). There was no evidence for an association between inflammation markers at baseline and anxiety disorders at follow-up. CONCLUSIONS: The prospective association between agoraphobia at baseline and hsCRP levels over the follow-up period suggests that chronic low-grade inflammation may be a consequence of this condition. The decrease in IL-6 in PTSD also requires further investigation. No evidence was found for chronic low-grade inflammation as a predictor of future anxiety disorders.


Subject(s)
Agoraphobia/blood , Anxiety Disorders/blood , C-Reactive Protein , Inflammation/blood , Interleukin-6/blood , Stress Disorders, Post-Traumatic/blood , Tumor Necrosis Factor-alpha/blood , Adult , Biomarkers/blood , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies
6.
Curr Neuropharmacol ; 15(3): 380-385, 2017 04.
Article in English | MEDLINE | ID: mdl-28503109

ABSTRACT

OBJECTIVES: Early psychopathology in children diagnosed with Bipolar Disorder (BD) remains poorly characterized. Parental retrospective reports provide helpful details on the earliest manifestations and their evolution over time. These symptoms occur early in the course of BD, often before a formal diagnosis is made and/or treatment is implemented, and are of great importance to early recognition and prevention. METHODS: Parents of pre-pubertal children and adolescents with DSM-IV diagnoses of BD attending an outpatient mood disorders clinic provided retrospective ratings of 37 symptoms of child psychopathology. Stability and comorbidity of diagnoses were evaluated, and severity of symptoms for each subject was assessed by identifying the earliest occurrence of the reported symptoms causing impairment. RESULTS: Severe mood instability, temper tantrums, anxiety symptoms, sleep disturbances and aggression were among the most common signs of psychopathology reported in children diagnosed with BD before puberty. Symptoms were already apparent in the first three years in 28%, and formal diagnoses were made before the age of 8 y in the majority of cases. CONCLUSIONS: Retrospective parental reports of early symptoms of psychopathology in pre-pubertal children with BD revealed a very early occurrence of affective precursors (irritability and mood dysregulation) and clinical risk factors like impulsive aggression and anxiety that can precede the syndromal onset of mania by several years. These findings support previous reports suggesting a progression of symptoms from abnormal, non-specific presentations to sub-threshold and finally syndromal BD. The importance of early identification and intervention is discussed.


Subject(s)
Anxiety Disorders/etiology , Bipolar Disorder/complications , Bipolar Disorder/psychology , Mood Disorders/etiology , Parents/psychology , Sleep Wake Disorders/etiology , Adolescent , Adult , Aged , Bipolar Disorder/diagnosis , Bipolar Disorder/therapy , Child , Child, Preschool , Disease Progression , Female , Humans , Male , Middle Aged , Outpatients , Psychopathology , Retrospective Studies , Risk Factors , Surveys and Questionnaires , Young Adult
7.
CNS Spectr ; 22(2): 203-219, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28421980

ABSTRACT

A significant minority of people presenting with a major depressive episode (MDE) experience co-occurring subsyndromal hypo/manic symptoms. As this presentation may have important prognostic and treatment implications, the DSM-5 codified a new nosological entity, the "mixed features specifier," referring to individuals meeting threshold criteria for an MDE and subthreshold symptoms of (hypo)mania or to individuals with syndromal mania and subthreshold depressive symptoms. The mixed features specifier adds to a growing list of monikers that have been put forward to describe phenotypes characterized by the admixture of depressive and hypomanic symptoms (e.g., mixed depression, depression with mixed features, or depressive mixed states [DMX]). Current treatment guidelines, regulatory approvals, as well the current evidentiary base provide insufficient decision support to practitioners who provide care to individuals presenting with an MDE with mixed features. In addition, all existing psychotropic agents evaluated in mixed patients have largely been confined to patient populations meeting the DSM-IV definition of "mixed states" wherein the co-occurrence of threshold-level mania and threshold-level MDE was required. Toward the aim of assisting clinicians providing care to adults with MDE and mixed features, we have assembled a panel of experts on mood disorders to develop these guidelines on the recognition and treatment of mixed depression, based on the few studies that have focused specifically on DMX as well as decades of cumulated clinical experience.


Subject(s)
Antidepressive Agents/therapeutic use , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/drug therapy , Guideline Adherence , Algorithms , Antidepressive Agents/adverse effects , Antimanic Agents/adverse effects , Antimanic Agents/therapeutic use , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Bipolar Disorder/classification , Bipolar Disorder/psychology , Depressive Disorder, Major/classification , Depressive Disorder, Major/psychology , Depressive Disorder, Treatment-Resistant/classification , Depressive Disorder, Treatment-Resistant/diagnosis , Depressive Disorder, Treatment-Resistant/drug therapy , Depressive Disorder, Treatment-Resistant/psychology , Diagnosis, Differential , Diagnostic and Statistical Manual of Mental Disorders , Drug Substitution , Drug Therapy, Combination , Electroconvulsive Therapy , Humans , Psychiatric Status Rating Scales , Self Report , Treatment Outcome
8.
CNS Spectr ; 22(2): 120-125, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27831463

ABSTRACT

The newly introduced Mixed Features Specifier of Major Depressive Episode and Disorder (MDE/MDD) is especially challenging in terms of pharmacological management. Prior to the publication of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the symptoms of the mixed features specifier were intradepressive hypomanic symptoms, always and only associated with bipolar disorder (BD). Intradepressive hypomanic symptoms, mostly referred to as depressive mixed states (DMX), have been poorly characterized, and their treatment offers significant challenges. To understand the diagnostic context of DMX, we trace the nosological changes and collocation of intradepressive hypomanic symptoms, and examine diagnostic and prognostic implications of such mixed features. One of the reasons so little is known about the treatment of DMX is that depressed patients with rapid cycling, substance abuse disorder, and suicidal ideation/attempts are routinely excluded from clinical trials of antidepressants. The exclusion of DMX patients from clinical trials has prevented an assessment of the safety and tolerability of short- and long-term use of antidepressants. Therefore, the generalization of data obtained in clinical trials for unipolar depression to patients with intradepressive hypomanic features is inappropriate and methodologically flawed. A selective review of the literature shows that antidepressants alone have limited efficacy in DMX, but they have the potential to induce, maintain, or worsen mixed features during depressive episodes in BD. On the other hand, preliminary evidence supports the effective use of some atypical antipsychotics in the treatment of DMX.


Subject(s)
Antidepressive Agents/adverse effects , Antidepressive Agents/therapeutic use , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/drug therapy , Bipolar Disorder/classification , Bipolar Disorder/psychology , Clinical Trials as Topic , Comorbidity , Depressive Disorder, Major/classification , Depressive Disorder, Major/psychology , Diagnosis, Differential , Diagnostic and Statistical Manual of Mental Disorders , Drug Therapy, Combination , Guideline Adherence , Humans , Selection Bias , Treatment Outcome
9.
J Affect Disord ; 193: 165-74, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26773919

ABSTRACT

BACKGROUND: The role of environmental risk factors in the development of bipolar disorder (BD) is not well characterized. We evaluate the prevalence, duration, and predictive value of environmental exposures for BD in longitudinal studies. METHODS: We conducted a systematic search of PubMed, Scopus and PsychINFO databases until April 01, 2015, using the following words in combination: prenatal exposure; maternal exposure; trauma; childhood abuse; alcoholism; cannabis; smoking; cocaine; central stimulants; opioids; uv light; pollution; global warming; vitamin d AND bipolar disorder. Additional references were obtained through cross-referencing. We included (1) longitudinal cohort studies or case-control studies nested within longitudinal designs; (2) studies of subjects without lifetime BD diagnoses at initial assessment and a diagnosis of BD at follow-up by clinical or structured assessment. Familial-risk studies were excluded. We tabulated details of study-design, exposure, diagnostic criteria, risk of bipolar disorder expressed as odd ratio (OR), relative risk (RR) or hazard ratio (HR). RESULTS: Of 2119 studies found, 22 met inclusion criteria. Risk factors identified can be grouped in 3 clusters: neurodevelopment (maternal influenza during pregnancy; indicators of fetal development), substances (cannabis, cocaine, other drugs - opioids, tranquilizers, stimulants, sedatives), physical/psychological stress (parental loss, adversities, abuses, brain injury). LIMITATIONS: Heterogeneity of designs and methodology prevented the use of meta-analysis of the findings; studies did not provide sensitivity, specificity and predictive value of the risk factors identified; case-control studies classify cases based on diagnostic membership, but do not control for familial or genetic liability; methods for determining the exposures varied among studies. CONCLUSION: Only preliminary evidence exists that exposure to viral infection, substances or trauma increase the likelihood of BD. Given the limited data available, the specificity, sensitivity and predictive value could not be computed. As exposures are sometimes amenable to prevention, further research is needed.


Subject(s)
Bipolar Disorder/epidemiology , Bipolar Disorder/etiology , Environmental Exposure/adverse effects , Virus Diseases/epidemiology , Wounds and Injuries/epidemiology , Humans , Longitudinal Studies , Prevalence , Risk Factors
10.
J Clin Psychiatry ; 76(5): 614-24, 2015 May.
Article in English | MEDLINE | ID: mdl-26035191

ABSTRACT

OBJECTIVE: To evaluate the presence of affective signs and symptoms as precursors of bipolar disorder in prospective studies, including assessment of their prevalence, duration, and predictive value. DATA SOURCES: We followed PRISMA guidelines to search PubMed, CINAHL, PsycINFO, EMBASE, SCOPUS, and ISI Web of Science databases to May 31, 2013, using the terms bipolar disorder AND (antecedent* OR predict* OR prodrom* OR prospect*) AND (diagnosis OR development). Hand searching of identified reports led to additional relevant references. STUDY SELECTION: We included only English-language articles containing (1) prospective, longitudinal studies with at least 2 structured clinical assessments (intake and follow-up); (2) no previous DSM-III or DSM-IV diagnoses of bipolar I or bipolar II; and (3) diagnostic outcome of bipolar I or bipolar II. Studies of subjects at familial risk of bipolar disorder were excluded, as these have been reviewed elsewhere. DATA EXTRACTION: We tabulated details of study design, outcomes, precursors, and predictive value. Only studies reporting a positive predictive association were included. RESULTS: In 26 published reports meeting selection criteria, methods varied widely in terms of design, duration of follow-up, ages, and populations investigated. Despite such heterogeneity in methods, findings were notably consistent. Precursors of bipolar disorder include mood lability, subsyndromal and major depression, subsyndromal hypomanic symptoms with or without major depression, cyclothymia and bipolar not otherwise specified, major depression with psychotic features, and other psychotic disorders. Bipolar disorder was also predicted by juvenile onset of major depression as well as frequency and loading of hypomanic or depressive symptoms. CONCLUSIONS: Despite the limitations of published reports, prospectively identified precursors of bipolar disorder typically arose years prior to syndromal onset, often with significant early morbidity and disability. Prospectively identified precursors of bipolar disorder are generally consistent with findings in retrospective and family-risk studies. Combining precursors and other risk factors may increase predictive value, support earlier diagnosis, improve treatment, and limit disability in bipolar disorder.


Subject(s)
Bipolar Disorder/epidemiology , Prodromal Symptoms , Bipolar Disorder/diagnosis , Humans
11.
Curr Psychiatry Rep ; 17(8): 604, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26084666

ABSTRACT

Attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BD) are neurodevelopmental disorders with onset in childhood and early adolescence, and common persistence in adulthood. Both disorders are often undiagnosed, misdiagnosed, and sometimes over diagnosed, leading to high rates of morbidity and disability. The differentiation of these conditions is based on their clinical features, comorbidity, psychiatric family history course of illness, and response to treatment. We review recent relevant findings and highlight epidemiological, clinical, family history, course, and treatment-response differences that can aid the differential diagnosis of these conditions in an outpatient pediatric setting.


Subject(s)
Attention Deficit Disorder with Hyperactivity/diagnosis , Attention Deficit Disorder with Hyperactivity/epidemiology , Bipolar Disorder/diagnosis , Bipolar Disorder/epidemiology , Adolescent , Affect , Aggression , Antidepressive Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/psychology , Bipolar Disorder/drug therapy , Bipolar Disorder/psychology , Central Nervous System Stimulants/therapeutic use , Child , Circadian Rhythm , Comorbidity , Diagnosis, Differential , Disabled Children , Humans , Learning , Neurodevelopmental Disorders/diagnosis , Neurodevelopmental Disorders/epidemiology , Persons with Mental Disabilities , Psychotic Disorders/diagnosis , Psychotic Disorders/epidemiology , Sleep , Suicidal Ideation , Treatment Outcome
12.
J Affect Disord ; 176: 18-23, 2015 May 01.
Article in English | MEDLINE | ID: mdl-25687279

ABSTRACT

BACKGROUND: Mixed states have been a fundamental part of Kraepelin׳s conceptualization of the manic-depressive illness. However, after Kraepelin, the study of mixed states was not of great interest, until the publication of the RDC criteria (1978) and then the DSM-III edition (1980), where criteria for mixed manic states were operationalized. The most notable victims of DSM nosology were depressive mixed states, in particular depression with flight of ideas and excited (agitated) depression. METHODS: We briefly review the clinical work of Athanasios Koukopoulos on depressive mixed states (in particular agitated depression) pointing out the diagnostic and therapeutic contributions, especially in the lights of Koukopoulos׳ first description of depressive mixed syndrome in 1992. RESULTS: The mixed depressive syndrome is not a transitory state but a state of long duration, which may last weeks or several months. The clinical picture is characterized by dysphoric mood, emotional lability, psychic and/or motor agitation, talkativeness, crowded and/or racing thoughts, rumination, initial or middle insomnia. Impulsive suicidal attempts may be frequent. The family observes incessant complaints, irritability, occasional verbal outbursts, occasional physical aggression, and occasional hypersexuality. Treatment with antipsychotics and ECT is very effective; antidepressants can worsen the clinical picture. LIMITATIONS: Selective but not systematic review of the literature on depressive mixed states. Relatively little research data is currently available for validation of the criteria proposed by Koukopoulos. CONCLUSIONS: Koukopoulos׳ proposal of mixed depression, besides its diagnostic implications, clearly identifying it as manifestations of bipolar disorder, allows for better clinical characterization of cases and improves treatment decisions.


Subject(s)
Bipolar Disorder/classification , Bipolar Disorder/diagnosis , Depressive Disorder, Major/classification , Depressive Disorder, Major/diagnosis , Genetic Diseases, X-Linked/classification , Genetic Diseases, X-Linked/diagnosis , Adult , Age of Onset , Antidepressive Agents/therapeutic use , Bipolar Disorder/drug therapy , Depression , Depressive Disorder, Major/drug therapy , Diagnosis, Differential , Diagnostic and Statistical Manual of Mental Disorders , Female , Genetic Diseases, X-Linked/drug therapy , Humans , Irritable Mood , Psychomotor Agitation
13.
J Affect Disord ; 168: 314-21, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25086290

ABSTRACT

BACKGROUND: Early phases and suspected precursor states of bipolar disorder are not well characterized. We evaluate the prevalence, duration, clinical features and predictive value of non-affective psychopathology as clinical risk factors for bipolar disorder in prospective studies. METHODS: We screened PubMed, CINAHL, PsycINFO, Embase, SCOPUS, and ISI-Web of Science databases from inception up to January 31, 2014, following PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and searched: bipolar disorder AND [antecedent⁎ OR predict⁎ OR prodrom⁎ OR prospect⁎ OR risk⁎] AND [diagnosis OR development]. We included only English language reports on prospective, longitudinal studies with two structured clinical assessments (intake and follow-up); no DSM intake diagnosis of bipolar-I or -II; diagnostic outcome was bipolar-I or -II. Details of study design, risk factors, and predictive value were tabulated. RESULTS: We found 16 published reports meeting selection criteria, with varying study design. Despite heterogeneity in methods, findings across studies were consistent. Clinical risk factors of bipolar disorder were early-onset panic attacks and disorder, separation anxiety and generalized anxiety disorders, conduct symptoms and disorder, ADHD, impulsivity and criminal behavior. LIMITATIONS: Since risk factors identified in some prospective studies are predictive of other conditions besides bipolar disorder, these preliminary findings require replication, and their sensitivity, specificity and predictive value need to be assessed. CONCLUSIONS: Clinical risk factors for bipolar disorder typically arise years prior to syndromal onset, include anxiety and behavioral disorders with unclear sensitivity and specificity. Prospectively identified clinical risk factors for bipolar disorder are consistent with retrospective and family-risk studies. Combining clinical risk factors with precursors and family-risk may improve early identification and timely and appropriate treatment of bipolar disorder.


Subject(s)
Bipolar Disorder/diagnosis , Bipolar Disorder/epidemiology , Anxiety Disorders/epidemiology , Attention Deficit Disorder with Hyperactivity/epidemiology , Comorbidity , Crime/statistics & numerical data , Female , Humans , Impulsive Behavior , Panic Disorder/epidemiology , Prevalence , Prospective Studies , Retrospective Studies , Risk Factors
15.
J Affect Disord ; 148(1): 129-35, 2013 May 15.
Article in English | MEDLINE | ID: mdl-23219059

ABSTRACT

OBJECTIVES: Compare reported rates of mood-shifts from major depression to mania/hypomania/mixed-states during antidepressant (AD)-treatment and rates of diagnostic change from major depressive disorder (MDD) to bipolar disorder (BPD). METHODS: Searching computerized literature databases, followed by summary analyses. RESULTS: In 51 reports of patients diagnosed with MDD and treated with an AD, the overall risk of mood-switching was 8.18% (7837/95,786) within 2.39 ± 2.99 years of treatment, or 3.42 (95% CI: 3.34-3.50) %/year. Risk was 2.6 (CI: 2.5-2.8) times greater with/without AD-treatment by meta-analysis of 10 controlled trials. Risk increased with time up to 24 months of treatment, with no secular change (1968-2012). Incidence rates were 4.5 (CI: 4.1-4.8)-times greater among juveniles than adults (5.62/1.26 %/year; p<0.0001). In 12 studies the overall rate of new BPD-diagnoses was 3.29% (1928/56,754) within 5.38 years (0.61 [0.58-0.64] %/year), or 5.6-times lower (3.42/0.61) than annualized rates of mood-switching. CONCLUSIONS: AD-treatment was associated with new mania-like responses in 8.18% of patients diagnosed with unipolar MDD. Contributions to mood-switching due to unrecognized BPD versus mood-elevating pharmacological effects, as well as quantitative associations between switching and later diagnosis of BPD not associated with AD-treatment remain uncertain. LIMITATIONS: Rates and definitions of mood-switching with ADs varied greatly, exposure-times rarely were precisely defined, and there was little information on predictive associations between mood-switches and BPD-diagnosis.


Subject(s)
Antidepressive Agents/adverse effects , Bipolar Disorder/chemically induced , Depressive Disorder, Major/drug therapy , Humans , Randomized Controlled Trials as Topic , Risk Assessment , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...